Sculptra (injectable poly-L-lactic acid).
As contemporary antiviral therapy provides patients who have HIV effective long-term management of their disease, the prevalence of facial HIV-associated lipoatrophy is increasing. Sculptra (Dermik Laboratories, Berwyn, Pennsylvania) (injectable poly-L-lactic acid) is US Food and Drug Administration approved for the treatment of HIV-associated lipoatrophy and has been shown to increase skin thickness for up to 2 years. The number of treatment sessions depends on the volume of deficiency to be treated. As is true for any cosmetic treatment, expectations must be carefully managed, especially considering the frequent need for multiple Sculptra treatments. The few adverse events resulting from poly-L-lactic acid injections consist mainly of subcutaneous nodule formation and local bruising.
Keni
Sanjay P
SP
Department of Otolaryngology-Head & Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Sidle
Douglas M
DM
D000273:Adipose Tissue / Q000187:drug effects / Q000473:pathology; D001284:Atrophy / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D002482:Cellulose / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007279:Injections, Subcutaneous; D019344:Lactic Acid / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D008353:Mannitol / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D011108:Polymers / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D015595:Skin Aging / Q000187:drug effects*
C482305:New-Fill; D011108:Polymers; D019344:Lactic Acid; D008353:Mannitol; D002482:Cellulose